Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of the addition of idelalisib
to ofatumumab on progression-free survival (PFS) in participants with previously treated
chronic lymphocytic leukemia (CLL).